Group items tagged

Dementia and Alzheimer's disease remained the leading cause of death in England and Wales in 2023, maintaining the pre-pandemic trend, according to the latest data from the Office for National Statistics (ONS). The figures reveal that there were 66,876 deaths with an underlying cause of dementia and Alzheimer's disease, accounting for 11.6% of all deaths registered that year. In response to this growing health concern, Luye Pharma is hosting a free special educational webinar on 6 November 2024 (timing: 18:30 - 20:00) for healthcare professionals. Titled "Treating Dementia in 2024: Optimising Pathways Between Primary and Secondary Care," the online session will focus on addressing the ever-increasing challenges in dementia treatment and how to optimise pathways between primary and secondary care. The webinar will feature expert speakers from the field of dementia care, including Dr. Jill Rasmussen, Primary Care Specialist in dementia, mental health, and intellectual disabilities; Delia Bashara, Consultant Pharmacist for the Mental Health of Older Adults and Dementia at South London and Maudsley NHS Foundation Trust; and Khaleel Loonat, Senior Clinical Pharmacist and Advanced Clinical Practitioner.

Alliance Healthcare UK team members Nick Atkins, Swansea Service Centre Manager, and Karl Goodall, Swansea Driver Team Manager, have climbed Pen y Fan in South Wales to support the Alzheimer's Society and raise money for dementia. The pair raised over £1,500, a cause close to Nick's heart, as his mother is a dementia patient. Dementia mainly affects people aged 65 and over, with 65 per cent of the 944,000 individuals living with dementia in the UK being women. Nick and Karl, dressed as 'glamorous grannies' with wigs, tights, and dresses, completed the mountain trek in six hours, carrying an Alliance Healthcare medicines cool box weighing over 35 kg. Alzheimer's Society supports people with dementia and their carers through national care and research efforts. Alzheimer's Society Cymru is the sole UK dementia charity funding both biomedical and care research.

A new study published in The Lancet has revealed that a total of 1.7 million people could be living with dementia in England and Wales by 2040. The research highlighted increasing numbers of people who will suffer from Alzheimer's. The disease would massively increase the burden on the healthcare system. The research was led by University of College London (UCL). Lead researcher, Dr Yuntao Chen said, "It is shocking to think that the number of people living with dementia by 2040 may be up to 70 per cent higher than if dementia incidence had continued to decline. "Not only will this have a devastating effect on the lives of those involved but it will also put a considerably larger burden on health and social care than current forecasts predict.

The Integrated Care Systems (ICSs) provide an opportunity to break the silo mentality in the health and care sector, National Pharmacy Association (NPA) chair Andrew Lane told MPs. While giving evidence to the Health and Social Care Select Committee on 6 December about the effectiveness of ICSs, Lane also poured cold water on newspaper reports that community pharmacists will be drafted in to break the NHS strike, as he reiterated the call for a "properly costed and funded environment." "We've been in different silos historically and ICSs are an opportunity to pull all systems together for the benefit of patients," he told committee members. Lane pointed to dementia-trained pharmacy delivery drivers and the Discharge Medicines Service as instances where the influence of community pharmacy already stretches beyond primary care into hospitals and social care. "We've seen pharmacists prescribe and get UTIs off doctors' desks, so we are starting to release capacity [in the system] and we're on that clinical journey. We welcome that, but it has to be with the right level of funding," he added.

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease. Clinical trial evidence suggests that the monthly injection can slow Alzheimer's disease progression by 4 to 7 months.

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease.

A comprehensive cohort study has shed light on the benefits and risks associated with weight-loss drugs, offering valuable insights for clinical care and future research. Published in Nature Medicine on 20 January 2024, the study found the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs)-used to treat diabetes and obesity-associated with a reduced risk of substance use disorders (including alcohol, cannabis, opioid and stimulant use disorders). Weight-loss drug use was also linked to decreased risks of psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. However, the use of GLP-1RAs was not without risks, as researchers identified an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic conditions, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis associated with their use. The analysis, utilising the U.S. Department of Veterans Affairs databases, compared 215,970 GLP-1 RA users with patients using sulphonylureas (n=159,465), DPP4 inhibitors (n=117,989), SGLT2 inhibitors (n=258,614), or a composite of the three (n=536,068).